Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study

Investigaciones expone trabajos que pueden aún no tener evidencias suficientes por su actualidad.

Regression of ECG-LVH is Associated with Lower Risk of New-Onset Heart Failure and Mortality in Patients with Isolated Systolic Hypertension; The LIFE Study

Por: Anne Cecilie K. Larstorp, Peter M. Okin, Richard B. Devereux, Michael H. Olsen3, Hans Ibsen, Björn Dahlöf, Sverre E. Kjeldsen y Kristian Wachtell.  American Journal of Hypertension (2012); 25 10, 1101–1109.

Hypertension and electrocardiographic left ventricular hypertrophy (ECG-LVH) are strong predictors of heart failure (HF). It is unclear whether regression of ECG-LVH during treatment predicts less new-onset HF in patients with isolated systolic hypertension (ISH).
Regression of time-varying Cornell product was associated with similar reductions in risk of new-onset HF and the combined endpoint of HF or death in ISH and non-ISH patients.